CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Berkley Heights, New Jersey

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

    Phase

    2

    Span

    72 weeks

    Sponsor

    Janssen Research & Development, LLC

    Plainfield, Indiana

    Recruiting

  • Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Phase

    3

    Span

    87 weeks

    Sponsor

    Eli Lilly and Company

    Plainfield, Indiana

    Recruiting

  • A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

    Phase

    3

    Span

    142 weeks

    Sponsor

    Janssen Research & Development, LLC

    Plainfield, Indiana

    Recruiting

  • Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

    Phase

    3

    Span

    204 weeks

    Sponsor

    Alumis Inc

    Plainfield, Indiana

    Recruiting

  • Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

    DARWIN is a randomized, active-comparator, double-blind, parallel-group, Phase IV study evaluating the effect of albuterol/budesonide (AIRSUPRA) compared to albuterol administered as-needed in response to symptoms on changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Approximately 15 sites in the United States of America will enroll adult participants with mild asthma who use albuterol as a rescue inhaler and who do not take ICS as maintenance therapy. The study will be divided in 2 periods (Lead-in Period and Treatment Period) and the total duration of the study for each participant could be up to 15 weeks, with a visit frequency of once every 4 weeks: - Lead-In Period: Up to 3 weeks - Treatment Period: 12 weeks

    Phase

    4

    Span

    61 weeks

    Sponsor

    AstraZeneca

    Plainfield, Indiana

    Recruiting

  • A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

    This study consists of a core and extension periods. The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12. The Core period consists of: - Screening period (up to 4 weeks): During the screening period, participants who have provided informed consent will be assessed for study eligibility. - Double-blind, placebo-controlled treatment period (24 weeks): 24 weeks of double-blind treatment with remibrutinib or placebo. - Open-label treatment period (28 weeks): 28 weeks of open-label treatment with remibrutinib. - Follow-up period: 4 weeks of treatment free follow-up. The open-label extension period consists of observation and treatment period. At the end of the core period of the study, if participants continue to experience symptoms, they will transition to the treatment period in OLE. If they do not experience symtpoms they will transition to the observation period in the OLE. The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib

    Phase

    3

    Span

    265 weeks

    Sponsor

    Novartis Pharmaceuticals

    Plainfield, Indiana

    Recruiting

  • Observational Evaluation of Atopic Dermatitis in Pediatric Patients

    The study duration is 120 months.

    Phase

    N/A

    Span

    871 weeks

    Sponsor

    Sanofi

    Plainfield, Indiana

    Recruiting

  • A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

    This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

    Phase

    3

    Span

    145 weeks

    Sponsor

    Celldex Therapeutics

    Plainfield, Indiana

    Recruiting

  • Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

    Phase

    3

    Span

    109 weeks

    Sponsor

    Incyte Corporation

    Plainfield, Indiana

    Recruiting

  • A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

    Phase

    4

    Span

    85 weeks

    Sponsor

    Eli Lilly and Company

    Plainfield, Indiana

    Recruiting

1-10 of 23
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information